NCT07199088Recruiting
Comparative Efficacy and Safety of Acetazolamide Versus Metolazone as an Adjunct to Standard Therapy in Patients With Acute Decompensated Heart Failure
Source: ClinicalTrials.gov · Last updated 3 Oct 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This clinical trial aims to compare the efficacy and safety of acetazolamide versus metolazone as adjunctive treatments to standard therapy in patients with acute decompensated heart failure (ADHF). ADHF is a life-threatening condition, and current treatments often involve loop diuretics to alleviate volume overload. This study will assess the added benefit of acetazolamide and metolazone in improving decongestion, reducing hospital stays, and preventing complications such as renal dysfunction or electrolyte imbalances. Participants will be randomized to receive either acetazolamide or metolazone in addition to standard diuretic therapy. The trial will evaluate primary outcomes including successful decongestion, in-hospital mortality, and length of hospital stay, with secondary outcomes focusing on renal function, electrolyte disturbances, and overall safety. The study is conducted at Bahawal Victoria Hospital, Bahawalpur, and aims to provide valuable insights into the management of ADHF, especially in the Pakistani population.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 320 (estimated)
- First submitted
- 21 Sept 2025
- Start date
- 11 Oct 2025
- Primary completion date
- 16 Oct 2026
- Lead sponsor
- University of Health Sciences Lahore
- Diseases
- Heart failure
- NCT number
- NCT07199088
What you commit to
- Study type: Interventional
- Planned participants: 320
- From 11 Oct 2025 to the primary completion date, 16 Oct 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous use of acetazolamide or metolazone prior to the study period.
- Patients requiring renal replacement therapy during the hospitalization.
Other illness
- Known hypersensitivity or allergies to the study drugs (acetazolamide or metolazone) or their components.
- Severe hypotension (systolic blood pressure \< 90 mmHg) or other significant comorbidities like congenital cardiac illness requiring surgery.
- History of significant electrolyte imbalances or acid-base disturbances.
Lab values
- End-stage renal disease requiring dialysis or GFR \< 20 mL/min/1.73 m².
Other
- Patients with electrolyte disturbances, especially hypokalemia.
- Pregnant or breastfeeding women.
Who the study is looking for
- Aged 18 years or older.
- Diagnosed with Acute Decompensated Heart Failure (ADHF), with either preserved or reduced ejection fraction (EF).
- At least one clinical sign of volume overload, such as:
- Pleural effusion (confirmed by chest X-ray or ultrasound).
- Oedema or ascites (verified by abdominal ultrasonography).
- Plasma NT-proBNP level \> 1000 pg/mL or BNP level \> 250 ng/mL at screening.
- Receiving at least 40 mg of furosemide as oral maintenance therapy for at least one month prior to the study initiation.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Quaid e Azam Medical College , bahawalpur Coordinator of this site? Confirm its status | Chak Eighty-seven -Twelve Left | Pakistan | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.